Adalank is a vendor-assigned name, not a compound with a single verified structure. Catalog listings call it a modified Selank derivative, and some product blends label it 'Adalank NA Amidate' alongside Adamax, but the reported terminal modifications vary between sellers.
No peer-reviewed primary study of Adalank was located in PubMed, and no trial-registry record was found. The identity question has to be resolved before any Selank finding can be attached to it; this record deliberately does not treat Adalank as an established Selank analogue.
Key takeaways
- No primary paper, review, or registered trial using the name Adalank was located; the name appears in vendor catalogs and blend listings, not the indexed scientific literature.
- Vendor descriptions disagree on what Adalank is: 'modified Selank derivative,' 'Adalank NA Amidate,' and a component of an Adamax/Adalank blend are not chemically equivalent claims.
- Parent Selank has small human anxiety trials and rodent/in vitro work, but none of it tested a product called Adalank [1][2][3].
How it works
Parent Selank as the only reference point
There is no verified mechanism for Adalank because there is no verified structure. Selank, the parent it is compared to, is a tuftsin analogue reported to act as a GABA-A positive allosteric modulator and to influence BDNF and enkephalin signaling [2].
What a defined Adalank sequence would need to show
If a given Adalank product really is an N-acetyl amidated Selank sequence, those parent mechanisms might be relevant, but the listings do not establish that consistently. The honest mechanistic statement is that Adalank's target and activity are unknown until its sequence is defined and tested.
What has been studied in humans
No human study of Adalank was located. The nearest human evidence is for parent Selank: a 62-patient comparison with medazepam in generalized anxiety disorder and neurasthenia, and a 70-patient add-on comparison with phenazepam [1][3]. Both reported anxiolytic or benzodiazepine-sparing effects for Selank, and both were small, single-country studies without a clearly described randomized placebo arm [1][3]. They did not administer Adalank and cannot be used to claim that Adalank treats anxiety or is well tolerated.
Lab and animal studies
No cell or animal study naming Adalank was located. Parent Selank has rodent data, including prevention of ethanol-induced memory deficits and changes in hippocampal BDNF, and in vitro radioligand data consistent with GABA-A positive allosteric modulation [2]. Those experiments used characterized Selank, not an Adalank product. Because Adalank's sequence is not fixed across sellers, even a future Selank comparison would need to specify which Adalank structure was tested.
Research in detail
Comparative clinical study; 30 patients received Selank and 32 received medazepam, with Hamilton, Zung, and CGI ratings. · 62 patients with generalized anxiety disorder and neurasthenia.
Similar anxiolytic effects were reported, with additional antiasthenic and psychostimulant effects for Selank.
Evidence scope: Small, single-country, no clearly described randomization or placebo; Adalank itself was not tested or chemically defined.
Radioligand receptor-binding experiments on isolated brain cell membranes, including combinations with benzodiazepines. · In vitro rodent brain membrane preparations.
Selank altered [3H]GABA binding in a concentration-dependent manner consistent with positive allosteric modulation and modified the effects of diazepam and olanzapine.
Evidence scope: In vitro binding cannot establish in vivo effect, clinical anxiolysis, or anything about Adalank's unidentified structure.
Comparative clinical study of phenazepam alone (30) versus Selank plus phenazepam (40), with HDRS, CGI, UKU, cognitive tests, and SF-36. · 70 patients with anxiety-phobic, hypochondriac, or somatoform disorders.
The combination was associated with earlier HDRS improvement, fewer benzodiazepine side effects, and better quality of life.
Evidence scope: Add-on design, no clearly described randomization or placebo, parent peptide only; no Adalank arm.
The future: what's next for Adalank
- What is Adalank's actual amino-acid sequence and terminal chemistry, and is it the same molecule across the vendors using the name?
- Is Adalank a single peptide, a Selank analogue, or a blend component, and can any supplier document that with an issuer-verified structure-specific assay?
- Would a defined Adalank sequence show Selank-like GABA-A activity, or does the naming reflect marketing rather than pharmacology [2]?
